Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway

KRAS is mutated in about 20-25% of all human cancers and especially in pancreatic, lung and colorectal tumors. Oncogenic KRAS stimulates several pro-survival pathways, but it also triggers the trans-activation of pro-apoptotic genes. In our work, we show that G13D mutations of KRAS activate the MAPK...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Conti, Annalisa, Majorini, Maria Teresa, Elliott, Richard, Ashworth, Alan, Lord, Christopher J., Cancelliere, Carlotta, Bardelli, Alberto, Seneci, Pierfausto, Walczak, Henning, Delia, Domenico, Lecis, Daniele
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2015
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4484434/
https://ncbi.nlm.nih.gov/pubmed/26028667
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados